9939 — Kintor Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- HK$1.32bn
- HK$1.38bn
- CNY32.68m
Annual income statement for Kintor Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 34.2 | 0 | 0 | 5 | 32.7 |
| Cost of Revenue | |||||
| Gross Profit | 34.2 | 0 | -43.7 | -4.73 | 8.04 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 874 | 945 | 1,059 | 150 | 232 |
| Operating Profit | -840 | -945 | -1,059 | -145 | -200 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -842 | -953 | -1,069 | -155 | -203 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -842 | -954 | -1,061 | -155 | -200 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -842 | -954 | -1,061 | -155 | -200 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -842 | -954 | -1,061 | -155 | -200 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.36 | -2.37 | -2.27 | -0.343 | -0.407 |